Activation of histamine H3-receptors inhibits carrier-mediated norepinephrine release during protracted myocardial ischemia. Comparison with adenosine A1-receptors and alpha2-adrenoceptors

Circulation Research
M ImamuraRoberto Levi

Abstract

We previously showed that prejunctional histamine H3-receptors downregulate norepinephrine exocytosis, which is markedly enhanced in early myocardial ischemia. In the present study, we investigated whether H3-receptors modulate nonexocytotic norepinephrine release during protracted myocardial ischemia. In this setting, decreased pH(i) in sympathetic nerve endings sequentially leads to a compensatory activation of the Na+-H+ antiporter (NHE), accumulation of intracellular Na+, reversal of the neuronal uptake of norepinephrine, and thus carrier-mediated release of norepinephrine. Accordingly, norepinephrine overflow from isolated guinea pig hearts undergoing 20-minute global ischemia and 45-minute reperfusion was attenuated approximately 80% by desipramine (10 nmol/L) and 70% by 5-(N-ethyl-N-isopropyl)-amiloride (EIPA, 10 micromol/L), inhibitors of norepinephrine uptake and NHE, respectively. The H3-receptor agonist imetit (0.1 micromol/L) decreased carrier-mediated norepinephrine release by approximately 50%. This effect was blocked by the H3-receptor antagonist thioperamide (0.3 micromol/L), indicating that H-receptor activation inhibits carrier-mediated norepinephrine release. At lower concentrations, imetit (10 nmol/L) or EIP...Continue Reading

References

Dec 1, 1991·European Heart Journal·A SchömigG Richardt
Sep 1, 1991·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·J Linden
May 14, 1987·Nature·J M ArrangJ C Schwartz
May 1, 1995·Journal of Molecular and Cellular Cardiology·T KurzA Schömig
Apr 1, 1994·European Heart Journal·W Kübler, R H Strasser
Jun 1, 1993·Cardiovascular Research·A M Dart, X J Du

❮ Previous
Next ❯

Citations

Sep 12, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Joanna JozwiakStefan Dhein
May 1, 2013·European Journal of Pharmacology·Takeshi KoyamaYasuo Matsumura
Jun 18, 2003·Biochemical and Biophysical Research Communications·Motohiro KoyamaRoberto Levi
Jul 4, 1998·Trends in Pharmacological Sciences·R LeursH Timmerman
Oct 19, 1999·Neurochemistry International·T YamazakiT Kawada
Nov 5, 2010·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Masashi TawaYasuo Matsumura
Oct 21, 2011·The Journal of Pharmacology and Experimental Therapeutics·Narumi Hashikawa-HobaraRoberto Levi
Feb 28, 2001·Proceedings of the National Academy of Sciences of the United States of America·R B SilverR Levi
Dec 26, 2001·Proceedings of the National Academy of Sciences of the United States of America·Randi B SilverRoberto Levi
Nov 4, 2000·Expert Opinion on Investigational Drugs·C J Mackins, R Levi
Jul 14, 2012·Cardiology Research and Practice·Masashi TawaYasuo Matsumura
Jun 28, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Alessandro PiniArianna Carolina Rosa
Sep 4, 2016·Pharmacological Reviews·Daniel P Bermingham, Randy D Blakely
Jan 25, 2005·Autonomic Neuroscience : Basic & Clinical·Eunyoung YiJeffrey A Love
Oct 19, 2016·Molecular Pharmacology·Gustavo Nieto-AlamillaJosé-Antonio Arias-Montaño
Apr 13, 2004·Journal of Cardiovascular Pharmacology·Satoshi YamamotoYasuo Matsumura
Dec 20, 2003·American Journal of Physiology. Heart and Circulatory Physiology·Alicia C ReidRandi B Silver
Nov 10, 2013·The Journal of Pharmacology and Experimental Therapeutics·Andria L Del TrediciEthan S Burstein
Jan 14, 2004·The Journal of Pharmacology and Experimental Therapeutics·Christof BurgdorfGert Richardt
Mar 22, 2003·The Journal of Pharmacology and Experimental Therapeutics·Aaron J MarcusRoberto Levi
Apr 5, 2003·The Journal of Pharmacology and Experimental Therapeutics·Casilde SestiRoberto Levi
Jan 24, 2002·The Journal of Pharmacology and Experimental Therapeutics·Casilde SestiRoberto Levi
Dec 30, 1998·Journal of Cardiovascular Pharmacology·D L SnyderJ Roberts
Jul 19, 2002·American Journal of Physiology. Heart and Circulatory Physiology·Dunli WuHazel H Szeto
Jan 1, 2014·Allergo Journal International·Gianni MaroneFrancescopaolo Granata
Jul 19, 2002·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Siamak DavaniJean-Pierre Kantelip
Nov 11, 2010·Journal of Medicinal Chemistry·Michael BerlinManuel de Lera Ruiz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.